Literature DB >> 33442542

EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.

Kazuya Kariyama1, Kazuhiro Nouso1, Atsushi Hiraoka2, Akiko Wakuta1, Ayano Oonishi1, Teiji Kuzuya3, Hidenori Toyoda4, Toshifumi Tada5, Kunihiko Tsuji6, Ei Itobayashi7, Toru Ishikawa8, Koichi Takaguchi9, Akemi Tsutsui9, Noritomo Shimada10, Masatoshi Kudo11, Takashi Kumada4.   

Abstract

INTRODUCTION: The ALBI score is acknowledged as the gold standard for the assessment of liver function in patients with hepatocellular carcinoma (HCC). Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation. However, the complex calculation of the ALBI score limits its applicability. Therefore, we developed a simplified ALBI score, based on data from a large-scale HCC database. We used the data of 5,249 naïve HCC cases registered in eight collaborating hospitals.
METHODS: We developed a new score, the EZ (Easy)-ALBI score, based on regression coefficients of Alb and T.Bil for survival risk in a multivariate Cox proportional hazard model. We also developed the EZ-ALBI grade and EZ-ALBI-T grade as alternative options for the ALBI grade and ALBI-T grade and evaluated their stratifying ability.
RESULTS: The equation used to calculate the EZ-ALBI score was simple {[T.Bil (mg/dL)] - [9 × Alb (g/dL)]}; this value highly correlated with the ALBI score (correlation coefficient, 0.981; p < 0.0001). The correlation was preserved across different Barcelona clinic liver cancer grade scores (regression coefficient, 0.93-0.98) and across different hospitals (regression coefficient, 0.98-0.99), indicating good generalizability. Although a good agreement was observed between ALBI and EZ-ALBI, discrepancies were observed in patients with poor liver function (T.Bil, ≥3 mg/dL; regression coefficient, 0.877). The stratifying ability of EZ-ALBI grade and EZ-ALBI-T grade were good and their Akaike's information criterion values (35,897 and 34,812, respectively) were comparable with those of ALBI grade and ALBI-T grade (35,914 and 34,816, respectively).
CONCLUSIONS: The EZ-ALBI score, EZ-ALBI grade, and EZ-ALBI-T grade are useful, simple scores, which might replace the conventional ALBI score in the future.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  ALBI score; Child-Pugh score; Prognostic prediction

Year:  2020        PMID: 33442542      PMCID: PMC7768152          DOI: 10.1159/000508971

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  26 in total

1.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

Authors:  Fidel-David Huitzil-Melendez; Marinela Capanu; Eileen M O'Reilly; Austin Duffy; Bolorsukh Gansukh; Leonard L Saltz; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Experience with portacaval shunt for portal hypertension.

Authors:  G E WANTZ; M A PAYNE
Journal:  N Engl J Med       Date:  1961-10-12       Impact factor: 91.245

Review 3.  General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida
Journal:  Dig Dis       Date:  2015-10-21       Impact factor: 2.404

Review 4.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

5.  A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hirofumi Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Koji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Hepatol Res       Date:  2017-08-02       Impact factor: 4.288

6.  Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Michitaka Imai; Kouji Joko; Hironori Tanaka; Tsutomu Tamai; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Oncology       Date:  2019-07-15       Impact factor: 2.935

7.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Authors:  Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

8.  The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.

Authors:  Philip J Johnson; Sarah J Pirrie; Trevor F Cox; Sarah Berhane; Mabel Teng; Daniel Palmer; Janet Morse; Diana Hull; Gillian Patman; Chiaki Kagebayashi; Syed Hussain; Janine Graham; Helen Reeves; Shinji Satomura
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

Review 9.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

10.  Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi Kudo
Journal:  Cancer Med       Date:  2019-05-24       Impact factor: 4.452

View more
  4 in total

1.  Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-12-08       Impact factor: 11.740

2.  Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.

Authors:  Prooksa Ananchuensook; Supachaya Sriphoosanaphan; Sirinporn Suksawatamnauy; Nipaporn Siripon; Nutcha Pinjaroen; Nopavut Geratikornsupuk; Stephen J Kerr; Kessarin Thanapirom; Piyawat Komolmit
Journal:  BMC Gastroenterol       Date:  2022-06-14       Impact factor: 2.847

3.  Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy.

Authors:  Andreas Schmid; Miriam Arians; Thomas Karrasch; Jörn Pons-Kühnemann; Andreas Schäffler; Martin Roderfeld; Elke Roeb
Journal:  J Clin Med       Date:  2022-03-22       Impact factor: 4.241

4.  Preoperative aspartate aminotransferase to albumin ratio correlates with tumor characteristics and predicts outcome of hepatocellular carcinoma patients after curative hepatectomy: a multicenter study.

Authors:  Wei Peng; Junyi Shen; Junlong Dai; Shusheng Leng; Fei Xie; Yu Zhang; Shun Ran; Xin Sun; Tianfu Wen
Journal:  BMC Surg       Date:  2022-08-09       Impact factor: 2.030

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.